| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;66:1915-1918
© 1998 The Society of Thoracic Surgeons
a Department of Pharmacology and University of Pittsburgh Cancer Institute, Lung Cancer Basic Science Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
b Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
c Department of Dental Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
d Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Address reprint requests to Dr Siegfried, Department of Pharmacology, University of Pittsburgh, E1340 Biomedical Science Tower, Pittsburgh, PA 15261
e-mail: (siegfrie{at}server.pharm.pitt.edu)
Presented at the Thirty-third Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Feb 3–5, 1997.
Background. Hepatocyte growth factor (HGF) is a cytokine that is released after injury. It is a paracrine factor that is produced by mesenchymal cells; epithelial and endothelial cells respond to HGF through its receptor, the c-met protein. Hepatocyte growth factor induces cell growth and cell movement and is also highly angiogenic. Evidence from breast cancer patients suggests that HGF is a negative prognostic indicator for breast cancer and is associated with invasive disease.
Methods. We measured the HGF content in tumor tissue from 56 non–small cell lung cancer patients using the Western blot technique. The amount of HGF in tumor extracts was quantitated by densitometry after transfer of proteins to nitrocellulose and exposure to antibodies. Survival curves were generated based on clinical information obtained for each patient.
Results. Our data indicate that HGF is also a negative prognostic indicator in lung cancer. As in the study of breast cancer patients, HGF was associated with recurrence and poor survival; the relative risk was seen to increase with increasing HGF tumor content. At levels of HGF greater than 100 units, the relative risk was 10, compared with that in patients with an HGF level of 1 unit. Node-negative patients with an elevated HGF tumor content had a significantly poorer outcome than node-positive patients with a low HGF tumor content. The same relationship was observed if the patients were stratified by stage: elevated HGF was associated with stage I patients whose disease recurred and who died of their disease, and stage I patients with elevated HGF had a worse survival than higher stage patients with a low level of HGF.
Conclusions. These results suggest that elevated HGF may predict a more aggressive biology in non–small cell lung cancer patients. The level of HGF may be useful as an indicator of high risk in early stage lung cancer patients.
This article has been cited by other articles:
|
|
 |
|
  P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann. Onc., September 1, 2008; 19(9): 1605 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kong-Beltran, S. Seshagiri, J. Zha, W. Zhu, K. Bhawe, N. Mendoza, T. Holcomb, K. Pujara, J. Stinson, L. Fu, et al. Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer Cancer Res., January 1, 2006; 66(1): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer Chest, July 1, 2005; 128(1): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Sheen-Chen, Y.-W. Liu, H.-L. Eng, and F.-F. Chou Serum Levels of Hepatocyte Growth Factor in Patients with Breast Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 715 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, R. Jagadeeswaran, S. Jagadeesh, M. S. Tretiakova, V. Nallasura, E. A. Fox, M. Hansen, E. Schaefer, K. Naoki, A. Lader, et al. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non-Small Cell Lung Cancer Cancer Res., February 15, 2005; 65(4): 1479 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T C Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, and G Tonini Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer J. Clin. Pathol., June 1, 2004; 57(6): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, P. Le, C. Liang, J. Chan, D. Kiewlich, T. Miller, D. Harris, L. Sun, A. Rice, S. Vasile, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol. Cancer Ther., November 1, 2003; 2(11): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Maulik, T. Kijima, P. C. Ma, S. K. Ghosh, J. Lin, G. I. Shapiro, E. Schaefer, E. Tibaldi, B. E. Johnson, and R. Salgia Modulation of the c-Met/Hepatocyte Growth Factor Pathway in Small Cell Lung Cancer Clin. Cancer Res., February 1, 2002; 8(2): 620 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bechard, T. Gentina, M. Delehedde, A. Scherpereel, M. Lyon, M. Aumercier, R. Vazeux, C. Richet, P. Degand, B. Jude, et al. Endocan Is a Novel Chondroitin Sulfate/Dermatan Sulfate Proteoglycan That Promotes Hepatocyte Growth Factor/Scatter Factor Mitogenic Activity J. Biol. Chem., December 14, 2001; 276(51): 48341 - 48349. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
